Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

T3 + 3: 3 + 3 Design With Delayed Outcomes

Pharmaceutical Statistics(2024)10.1002/pst.2414Source: DataRank Database

T3 + 3: 3 + 3 Design With Delayed Outcomes is a research paper published in Pharmaceutical Statistics (2024). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 1.01)OA: hybridTopics (47)IDs (PubMed, PMC, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Mengyi Lu ORCID,Isabella Wan,Yu‐Min Wang ORCID,Leng Han ORCID,Yong Zang ORCID

Live enrichment

PubMed:38923150 PMC:PMC11602947 OpenAlex:https://openalex.org/W4400056122

National Institutes of Health

Grant: P30 CA082709

National Institutes of Health

Grant: R01 GM150808

National Institutes of Health

Grant: R21 CA264257

Ralph W. and Grace M. Showalter Research Trust award

FWCI

1.01

Citation Percentile

0.8%

Citation Trend

2025

2026

hybridLicense: cc-by-nc

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pst.2414

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pst.2414

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/pst.2414

journalhttps://doi.org/10.1002/pst.2414

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38923150

Fields of Study

Statistical Methods in Clinical TrialsOptimal Experimental Design MethodsHealth Systems, Economic Evaluations, Quality of LifeHumansMaximum Tolerated DoseClinical Trials, Phase I as TopicComputer SimulationResearch DesignTime FactorsDose-Response Relationship, DrugAntineoplastic AgentsAlgorithmsNeoplasmsTreatment Outcome

MeSH Terms

AlgorithmsAntineoplastic AgentsComputer SimulationDose-Response Relationship, DrugHumansNeoplasmsResearch DesignTime FactorsTreatment OutcomeClinical Trials, Phase I as TopicMaximum Tolerated Dose

Keywords

Isotonic regressionMaximum tolerated doseToxicityClinical trialOutcome (game theory)Research designDuration (music)Clinical study designComputer scienceLogistic regressionMedicineReliability engineeringStatisticsMathematicsInternal medicineEngineeringMachine learningOptimal designPhase I Clinical TrialsBayesian Adaptive DesignDelayed Outcome3 + 3 Design